Han media: China's new drug development capabilities are catching up with the US!
On August 23, South Korean media "Korea Economic Daily" published an article stating that after artificial intelligence (AI) and electric vehicles, China has also made significant progress in the biotechnology field.
According to Bloomberg, the number of new drugs developed in China last year exceeded 1,250. This not only surpassed the European Union but was almost on par with the United States (about 1,440). The new drug candidates from China are being recognized by pharmaceutical regulatory authorities in various countries as well as by pharmaceutical companies in the US and Europe. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) highly value the potential of Chinese new drugs.
Global pharmaceutical companies such as Merck, AstraZeneca, and Roche are actively acquiring biotechnology from Chinese pharmaceutical companies. In May this year, Pfizer signed a $1.2 billion technology transfer contract for next-generation anti-cancer candidate drugs with SanSheng Biopharma, a Chinese company.
China completely restructured its drug regulatory system in 2015. "Made in China 2025" also had the effect of concentrating investment in the biotechnology field. According to analysis, China has advantages in speed and cost at stages such as laboratory experiments, animal and human clinical trials. Bloomberg reported: "Since 2021, China has become a center for clinical trials and is trying to conduct the most new clinical trials globally."
Original: www.toutiao.com/article/1841233828353227/
Statement: This article represents the views of the author.